| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
23,530,000 |
| Market
Cap: |
55.30(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.71 - $4.47 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Oramed Pharmaceuticals is a pharmaceutical company. Co. is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. Co.'s primary product, ORMD-0801, is an orally ingestible insulin capsule for the treatment of diabetes. In addition to its key product, the ORMD-0801 insulin capsule, Co. is using its technology for an orally ingestible Glucagon-like peptide-1 capsule, or ORMD-0901. Co. is developing a drug candidate, a weight loss treatment in the form of an oral leptin capsule.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
26,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$53,014 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
0 |
0 |
0 |
13,325 |
| Total Sell Value |
$0 |
$0 |
$0 |
$167,195 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Reznick Yehuda |
Director |
– • – |
2024-04-17 |
4 |
A |
$0.00 |
$0 |
D/D |
29,800 |
29,800 |
|
- |
|
| Aghion Daniel |
Director |
– • – |
2024-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
3,750 |
38,820 |
|
- |
|
| Rozov Yadin |
Director |
– • – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
38,820 |
155,320 |
|
- |
|
| Mayer Arie |
Director |
– • – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
39,325 |
96,134 |
|
- |
|
| Hexter Joshua |
COO & CBO |
• – – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
180,500 |
481,833 |
|
- |
|
| Kidron Nadav |
President and CEO |
• • – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
329,000 |
1,781,098 |
|
- |
|
| Kidron Miriam |
Chief Scientific Officer |
• • – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
295,500 |
763,666 |
|
- |
|
| Silberman David |
Chief Financial Officer |
• – – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
136,500 |
366,500 |
|
- |
|
| Sank Leonard |
Director |
– • – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
39,325 |
98,021 |
|
- |
|
| Shapiro Benjamin |
Director |
– • – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
35,070 |
55,070 |
|
- |
|
| Aghion Daniel |
Director |
– • – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
35,070 |
35,070 |
|
- |
|
| Derovan Netanel |
Chief Legal Officer |
• – – |
2023-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
20,500 |
149,500 |
|
- |
|
| Hexter Joshua |
COO & CBO |
• – – |
2023-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
27,000 |
301,333 |
|
- |
|
| Kidron Miriam |
Chief Scientific Officer |
• • – |
2023-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
53,500 |
468,166 |
|
- |
|
| Silberman David |
Chief Financial Officer |
• – – |
2023-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
24,500 |
230,000 |
|
- |
|
| Kidron Nadav |
President and CEO |
• • – |
2023-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
120,000 |
1,452,098 |
|
- |
|
| Shapiro Benjamin |
Director |
– • – |
2023-05-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,900,000 |
|
26% |
|
| Shapiro Benjamin |
Director |
– • – |
2023-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
20,000 |
|
- |
|
| Rozov Yadin |
Director |
– • – |
2023-04-17 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
116,500 |
|
- |
|
| Hexter Joshua |
COO & CBO |
• – – |
2023-04-17 |
4 |
A |
$0.00 |
$0 |
D/D |
108,000 |
274,333 |
|
- |
|
| Mayer Arie |
Director |
– • – |
2023-04-17 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
56,809 |
|
- |
|
| Sank Leonard |
Director |
– • – |
2023-04-17 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
58,696 |
|
- |
|
| Kidron Miriam |
Chief Scientific Officer |
• • – |
2023-04-17 |
4 |
A |
$0.00 |
$0 |
D/D |
213,000 |
414,666 |
|
- |
|
| Derovan Netanel |
Chief Legal Officer |
• – – |
2023-04-17 |
4 |
A |
$0.00 |
$0 |
D/D |
81,000 |
129,000 |
|
- |
|
| Kidron Nadav |
President and CEO |
• • – |
2023-04-17 |
4 |
A |
$0.00 |
$0 |
D/D |
279,000 |
1,332,098 |
|
- |
|
140 Records found
|
|
Page 1 of 6 |
|
|
0.02 (0.86%) 
